Haemonetics Corporation $HAE Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its stake in Haemonetics Corporation (NYSE:HAE) by 11.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 148,290 shares of the medical instruments supplier’s stock after selling 19,413 shares during the quarter. Principal Financial Group Inc. owned 0.31% of Haemonetics worth $7,228,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust boosted its position in shares of Haemonetics by 11.6% during the second quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 152 shares during the period. Retirement Systems of Alabama lifted its stake in Haemonetics by 0.4% during the 2nd quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock worth $4,581,000 after acquiring an additional 256 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in Haemonetics by 3.9% during the 2nd quarter. Teacher Retirement System of Texas now owns 7,636 shares of the medical instruments supplier’s stock valued at $570,000 after acquiring an additional 285 shares during the period. Quantinno Capital Management LP grew its position in Haemonetics by 9.0% in the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after acquiring an additional 289 shares in the last quarter. Finally, CWC Advisors LLC. increased its stake in Haemonetics by 7.8% during the third quarter. CWC Advisors LLC. now owns 4,551 shares of the medical instruments supplier’s stock worth $222,000 after purchasing an additional 328 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on HAE. Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. Barrington Research set a $94.00 price objective on Haemonetics in a research report on Friday, February 6th. JPMorgan Chase & Co. increased their price objective on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Raymond James Financial reissued an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Finally, Citigroup decreased their price objective on Haemonetics from $88.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $84.44.

Haemonetics Trading Up 0.2%

HAE opened at $57.78 on Friday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The company has a market cap of $2.69 billion, a P/E ratio of 15.92, a PEG ratio of 1.21 and a beta of 0.28. The business’s 50-day simple moving average is $74.41 and its 200-day simple moving average is $64.60.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $338.97 million during the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities research analysts expect that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.